{
    "clinical_study": {
        "@rank": "95792", 
        "arm_group": [
            {
                "arm_group_label": "SP-01", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Granisetron Hydrochloride Tablet", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of SP-01 in\n      chemotherapy-induced nausea and vomiting (CINV) associated with the administration of\n      moderately or highly emetogenic (ME or HE) multi-day chemotherapy\uff0cwhich will provide\n      scientific and reliable clinical data in the drug registration in China."
        }, 
        "brief_title": "A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Chemotherapy-induced Nausea and Vomiting", 
        "condition_browse": {
            "mesh_term": [
                "Nausea", 
                "Vomiting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged \u2265 18years\n\n          -  Histologically and/or cytologically confirmed cancer\n\n          -  The physical status score ECOG \u2264 2\n\n          -  Life expectancy of \u22653 months\n\n          -  Will receive multi-day ME/HE chemotherapy (\u22652 days) with the emetogenic potential of\n             level 3-5\n\n          -  In accordance with the indication of chemotherapy and basic requirements;\n\n               -  Peripheral Haematology: Hb \u2265 9.0 g/dL, absolute neutrophil count \u2265 1.5\u00d710e9/L,\n                  platelet count \u2265 80\u00d710e9/L\n\n               -  Blood biochemistry: Total bilirubin < 1.25\u00d7ULN, ALT and AST \u2264 2.5\u00d7ULN; if liver\n                  metastasis, ALT and AST < 5\u00d7ULN, Creatinine \u2264 1\u00d7ULN, basic normal serum\n                  electrolyte (Na, Ka, Cl, Ca)\n\n               -  Other important organs function normally\n\n          -  Subjects voluntarily participate and signed the informed consent form"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "313", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937156", 
            "org_study_id": "SP-0103"
        }, 
        "intervention": [
            {
                "arm_group_label": "SP-01", 
                "description": "SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.", 
                "intervention_name": "SP-01 (Granisetron Transdermal Delivery System)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Granisetron Hydrochloride Tablet", 
                "description": "Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for \u2265 2 days.", 
                "intervention_name": "Granisetron Hydrochloride Tablet", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Granisetron"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "210002"
                }, 
                "name": "The 81st Hospital of P.L.A."
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Active-control, Double-blind, Double-dummy, Parallel-group, Multi-center Study to Assess the Efficacy and Safety of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Moderately or Highly Emetogenic (ME or HE) Multi-day Chemotherapy", 
        "overall_official": {
            "affiliation": "The 81st hospital of P.L.A.", 
            "last_name": "Shukui Qin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percentage of subjects achieving Complete Control (CC) of CINV from the first administration until 24 hour after the last administration of ME or HE multi-day chemotherapy", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937156"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Solasia Pharma K.K.", 
        "sponsors": {
            "collaborator": {
                "agency": "PROSWELL MEDICAL COMPANY", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Solasia Pharma K.K.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}